Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure

A S Androne, K Hryniewicz, R Goldsmith, A Arwady, S D Katz

Heart 2003;89:854–858

Objective: To characterise the effects of acetylcholinesterase inhibition with pyridostigmine on parasympathetic tone in patients with chronic heart failure (CHF).

Design: Prospective randomised, double blind crossover trial.

Setting: University hospital outpatient heart failure clinic.

Patients: 20 ambulatory subjects with stable CHF (mean age 55 years, mean ejection fraction 24%).

Interventions: Oral administration of a single dose of pyridostigmine 30 mg and matching placebo on separate days.

Main outcome measures: Heart rate recovery at one minute and three minutes after completion of maximal exercise.

Results: Heart rate recovery at one minute after exercise was significantly greater after administration of pyridostigmine than after administration of placebo (mean (SEM) 27.4 (3.2) beats/min v 21.4 (2.4) beats/min, p < 0.01). Heart rate recovery at three minutes after exercise did not differ after administration of pyridostigmine and placebo (mean (SEM) 44.4 (3.9) beats/min v 41.8 (3.6) beats/min, NS). Peak heart rate, peak oxygen uptake, peak respiratory exchange ratio, plasma noradrenaline (norepinephrine) concentrations, and plasma brain natriuretic peptide concentrations did not differ after administration of pyridostigmine and placebo.

Conclusions: Acetylcholinesterase inhibition with pyridostigmine increased heart rate recovery at one minute but not at three minutes after exercise. A specific effect of pyridostigmine on heart rate one minute after exercise suggests that pyridostigmine augments parasympathetic tone in patients with CHF.

Abnormalities in neuroendocrine regulation are thought to be important determinants of long term morbidity and mortality in patients with chronic heart failure (CHF). Among the major manifestations of neuroendocrine dysregulation are profound abnormalities in autonomic control, characterised by sympathetic overactivity and parasympathetic withdrawal. Inhibition of sympathetic overactivity with β-adrenergic receptor blocking agents improved survival in clinical trials in patients with CHF but there are few previous clinical investigations of parasympathomimetic agents in heart failure populations.

Acetylcholinesterase inhibitors increase parasympathetic neurotransmission through inhibition of the enzymatic breakdown of acetylcholine at cholinergic receptor sites in the autonomic nervous system. Pyridostigmine is a short acting, reversible acetylcholinesterase inhibitor used in the treatment of myasthenia gravis. Since CHF is characterised by withdrawal of parasympathetic tone, cholinesterase inhibition may restore autonomic balance with augmentation of parasympathetic neurotransmission. The effects of pyridostigmine on the parasympathetic nervous system in patients with CHF have not been previously reported.

Rapid deceleration of heart rate within the first minute after peak exercise is regulated primarily by reactivation of the parasympathetic nervous system. An attenuated decrease in the heart rate during the first minute of recovery after graded exercise has been previously described in patients with heart failure and is strongly associated with subsequent mortality risk in subjects with and without cardiovascular disease. Whether pharmacological modulation of parasympathetic function can effect changes in heart rate recovery after exercise is unknown.

Accordingly, the current study was undertaken to determine prospectively the acute effects of a single dose of oral pyridostigmine on parasympathetic function as assessed by measurement of heart rate recovery one minute after maximal exercise in ambulatory patients with stable CHF in a randomised, double blind, placebo controlled crossover trial. We hypothesised that augmentation of parasympathetic neurotransmission with pyridostigmine would increase early heart rate recovery after maximal exercise when compared with placebo.

METHODS

Study population

Eighteen men and two women with CHF were studied. Subjects between 21–75 years of age with CHF of more than three months’ duration, stable New York Heart Association (NYHA) functional class I to III symptoms for at least two months, and left ventricular ejection fraction ≤ 40% (determined by radionuclide angiography or echocardiography) were eligible for the study. Criteria for exclusion were history of potential contraindications to cholinergic stimulation (asthma, glaucoma, urinary retention), atrial fibrillation, sick sinus syndrome, previous implantation of a permanent pacemaker, acute coronary or cerebral vascular events within the past year, diabetes mellitus with peripheral neuropathy, systolic blood pressure < 90 or > 160 mm Hg, resting heart rate > 120 beats/min, or use of cholinesterase inhibitors.

Abbreviations: BNP, brain natriuretic peptide; CHF, chronic heart failure; NYHA, New York Heart Association; \( V_{\text{CO}} \), carbon dioxide production; \( V_{\text{E}} \), ventilation; \( V_{\text{O}} \), oxygen uptake.
exchange ratio, ventilatory anaerobic threshold, and \( V_{\text{E}} - V_{\text{CO}_2} \) slope were derived from gas exchange data with standard analysis of variance models appropriate for the crossover design. The relation between baseline clinical variables and heart rate recovery was assessed with simple linear regression. For all analyses, a two tailed \( p < 0.05 \) was used to infer significance.

RESULTS

**Clinical correlates of heart rate recovery**

Table 1 lists the clinical characteristics of the study population. Heart rate recovery at one minute after exercise was significantly greater in subjects with NYHA class I–II heart failure than in subjects with NYHA class III heart failure (29 (3) beats/min, \( r = 13 \) (1) beats/min, \( p < 0.01 \)) and was significantly greater in patients with normal \( V_{\text{E}} - V_{\text{CO}_2} \) slope than in patients with high \( V_{\text{E}} - V_{\text{CO}_2} \) slope (25 (3) beats/min, \( r = 14 \) (2) beats/min, \( p = 0.01 \)). Heart rate recovery one minute after exercise was significantly associated with peak \( V_{\text{O}_2} \) (\( r = 0.72, p < 0.01 \)) and \( V_{\text{E}} - V_{\text{CO}_2} \) slope during exercise (\( r = 0.62, p < 0.01 \)). Heart rate recovery at one minute after exercise did not differ between patients with ischaemic heart failure and those with other aetiologies of heart failure and was not significantly associated with age or left ventricular ejection fraction.

**Effects of study drug at rest**

Heart rate at rest was significantly decreased after pyridostigmine administration compared with placebo (65 (2) beats/min, \( r = 68 \) (2) beats/min, \( p < 0.05 \)). Mean arterial blood pressure at rest did not differ after administration of pyridostigmine and placebo (82 (2) mm Hg vs 82 (2) mm Hg). NS).

**Effects of study drug on exercise performance**

Heart rate, mean arterial pressure, oxygen consumption, respiratory exchange ratio, and \( V_{\text{E}} - V_{\text{CO}_2} \) slope did not differ during exercise after administration of pyridostigmine and placebo (table 2).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical characteristics of the 20 study patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean (SEM))</td>
<td>55 (3) (range 23–73)</td>
</tr>
<tr>
<td>Sex (n, M/F)</td>
<td>18/2</td>
</tr>
<tr>
<td>LVEF [% mean (SEM)]</td>
<td>24 (2) (range 10–40%)</td>
</tr>
<tr>
<td>NYHA class (n, I/II/III)</td>
<td>2/10/8</td>
</tr>
<tr>
<td>Aetiology [n, ischaemic/other]</td>
<td>9/11</td>
</tr>
<tr>
<td>( V_{\text{E}} - V_{\text{CO}_2} ) slope &gt;34 (n)</td>
<td>7</td>
</tr>
<tr>
<td>( \beta ) Blockers (n)</td>
<td>18</td>
</tr>
<tr>
<td>Digoxin (n)</td>
<td>12</td>
</tr>
<tr>
<td>ACE inhibitors (n)</td>
<td>18</td>
</tr>
<tr>
<td>Diuretics (n)</td>
<td>11</td>
</tr>
</tbody>
</table>

ACE, angiotensin converting enzyme; F, female; LVEF, left ventricular ejection fraction; M, male; NYHA, New York Heart Association; \( V_{\text{E}} - V_{\text{CO}_2} \), ratio of ventilation and carbon dioxide production during exercise.

www.heartjnl.com
Effects of study drug on postexercise heart rate recovery

Heart rate recovery at one minute after peak exercise after administration of pyridostigmine was significantly greater than that after administration of placebo (27.4 (3.2) beats/min vs 22.4 (2.4) beats/min, p < 0.01) (fig 1). Differences in heart rate recovery at one minute after peak exercise between pyridostigmine and placebo remained significant when adjusting for NYHA functional class, β blocker dose, digoxin use, and high VE–VCO₂ slope (all adjusted p < 0.01). NYHA functional class, dose of β adrenergic receptor antagonist, and digoxin use did not modify the effects of pyridostigmine on heart rate recovery one minute after peak exercise (NS for interaction terms). The effect of pyridostigmine on heart rate recovery one minute after peak exercise tended to be greater in subjects with normal VE–VCO₂ slope (difference for treatment groups 7.1 (2.3) beats/min) than in subjects with high VE–VCO₂ slope (difference for treatment groups 2.6 (1.3) beats/min, p = 0.17 for interaction term). Heart rate recovery at one minute after peak exercise tended to be greater in subjects with normal V̇O₂ at peak exercise than in subjects with high V̇O₂ at peak exercise (NS for interaction terms). The effect of pyridostigmine on heart rate recovery at one minute after peak exercise (NS for interaction terms). The effect of pyridostigmine on heart rate recovery at one minute after peak exercise tended to be greater in subjects with normal V̇O₂ at peak exercise than in subjects with high V̇O₂ at peak exercise (NS for interaction terms).

**Table 2** Exercise performance variables at anaerobic threshold and during exercise after administration of pyridostigmine and placebo

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pyridostigmine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR at AT (beats/min)</td>
<td>103 (5)</td>
<td>104 (4)</td>
</tr>
<tr>
<td>HR at peak exercise (beats/min)</td>
<td>129 (5)</td>
<td>129 (5)</td>
</tr>
<tr>
<td>V̇O₂ at AT (ml/kg/min)</td>
<td>12.2 (1.1)</td>
<td>11.6 (1.1)</td>
</tr>
<tr>
<td>V̇O₂ at peak exercise (ml/kg/min)</td>
<td>17.7 (1.5)</td>
<td>17.4 (1.5)</td>
</tr>
<tr>
<td>RER at peak exercise</td>
<td>1.05 (0.01)</td>
<td>1.04 (0.02)</td>
</tr>
<tr>
<td>Exercise VE–VCO₂ slope</td>
<td>34.2 (1.8)</td>
<td>33.7 (1.6)</td>
</tr>
<tr>
<td>MAP at peak exercise (mm Hg)</td>
<td>98 (2)</td>
<td>100 (2)</td>
</tr>
</tbody>
</table>

All values expressed as mean (SEM). AT, anaerobic threshold; HR, heart rate; MAP, mean arterial pressure; RER, respiratory exchange ratio; V̇O₂, oxygen consumption.

**Figure 1** Heart rate recovery (HRR, beats/min, mean with error bar indicating positive SEM) at one minute and three minutes after maximal exercise in 20 subjects with chronic heart failure after treatment with pyridostigmine (solid bars) or placebo (open bars). *p<0.01 v placebo.

**DISCUSSION**

The central finding of this study is that acetylcholinesterase inhibition with a single dose of 30 mg of pyridostigmine acutely increased heart rate recovery at one minute after maximal exercise in patients with stable CHF when compared with placebo.

Pyridostigmine is a reversible acetylcholinesterase inhibitor used in the treatment of myasthenia gravis at typical daily doses ranging from 240–480 mg. The pharmacological action of pyridostigmine is attributable to inhibition of the enzymatic breakdown of acetylcholine and consequent potentiation of cholinergic neurotransmission. The effects of pyridostigmine on cardiovascular function have been previously reported in normal subjects and patients with coronary artery disease and hypertension. Administration of single doses of 30–45 mg of pyridostigmine was associated with a 28% reduction in serum cholinesterase activity and decrease in resting heart rate of 5–7 beats/min in normal subjects and patients with cardiovascular disease. Pyridostigmine at these doses was well tolerated and was not associated with changes in heart rate during exercise or in response to mental stress, changes in arterial pressure, or changes in ventilatory or neuromuscular function.

Increased heart rate during progressive exercise is regulated by concomitant attenuation of parasympathetic activation and augmentation of sympathetic activation. Rapid deceleration of heart rate in the first minute after exercise is effected primarily by postexercise reactivation of the parasympathetic nervous system. The mechanisms for rapid reactivation of vagal tone immediately after exercise cessation are not fully characterised but are thought to be mediated in part by release of central inhibition and increased ventilatory tidal volumes at peak exercise. Withdrawal of sympathetic activation does not appear to have an important role in modulation of early heart rate recovery. The current findings of an increase in the magnitude of heart rate recovery at one minute of recovery but not at three minutes of recovery after administration of pyridostigmine are consistent with a specific augmentation of parasympathetic tone. A specific effect on parasympathetic tone is also supported by our finding that pyridostigmine and placebo did not differ (44.4 (3.9) beats/min v 41.8 (3.6) beats/min, NS) (fig 1).

**Table 3** Plasma brain natriuretic peptide and noradrenaline concentrations at rest and at peak exercise after administration of pyridostigmine and placebo

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pyridostigmine</th>
<th>Placebo</th>
<th>p Value Pyr v Plac</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma BNP</td>
<td>179 (73)</td>
<td>212 (74)*</td>
<td>*p&lt;0.05 v rest.</td>
</tr>
<tr>
<td>Plasma NA</td>
<td>447 (73)</td>
<td>1294 (151)*</td>
<td>*p&lt;0.05 v rest.</td>
</tr>
</tbody>
</table>

All values expressed as mean (SEM). BNP, brain natriuretic peptide; NA, noradrenaline; Plac, placebo; Pyr, pyridostigmine.
Pyridostigmine in heart failure

Pyridostigmine decreased heart rate at rest when compared with placebo but not at anaerobic threshold or at peak exercise. Evidence of a borderline significant interaction effect with VE–Vco2 slope is also consistent with a specific augmentation of parasympathetic tone, as pretreatment parasympathetic tone is greater in patients with normal VE–Vco2 slope than in patients with high VE–Vco2 slope.24,28 The lack of effect on plasma noradrenaline concentrations at rest or at peak exercise when compared with placebo suggests that the effects of pyridostigmine on heart rate recovery were not mediated by suppression of sympathetic activation.

Early heart rate recovery, as assessed by the exponential time constant of heart rate deceleration in the first 30 seconds after exercise and by frequency domain analysis of heart rate variability, is impaired in subjects with CHF when compared with normal subjects.5–10 Our findings are consistent with these previous studies and show that heart rate recovery is related to functional class, peak aerobic capacity, and VE–Vco2 slope. The observed association between heart rate recovery and these variables is in accord with previous reports that showed that baroreceptor sensitivity was closely related to functional status and VE–Vco2 slope in patients with CHF.8–10

Pharmacological modulation of parasympathetic function with scopolamine has been previously reported in subjects with heart failure. In contrast to pyridostigmine, which augments parasympathetic tone by inhibiting breakdown of endogenously released acetylcholine, scopolamine has dual effects on autonomic function that are dependent on the administered dose. At low dose scopolamine has a central vagomimetic effect, whereas at high dose scopolamine has a peripheral anticholinergic action. In patients with mild to moderate heart failure, short term courses of low dose scopolamine applied transdermally increased time domain and frequency domain indices of resting heart rate variability and improved baroreceptor sensitivity without an effect on exercise tolerance or the incidence and severity of ventricular arrhythmias.14–17 Practical long term administration of scopolamine has been limited by its narrow therapeutic range and consequent potential for anticholinergic side effects.9

An attenuated decrease in the heart rate during the first minute of recovery after peak exercise is strongly associated with subsequent mortality risk, independently of peak exercise workload, the presence or absence of myocardial perfusion defects, and peak heart rate in patients referred for clinical exercise testing.13–17 In patients with heart failure, autonomic dysfunction, as assessed by baroreceptor sensitivity and heart rate variability, is associated with increased mortality risk.18–20 Since the reported estimated slope of the relation between heart rate recovery and mortality risk in previous clinical studies was steep,19,20 it relatively small changes in heart rate recovery, such as those observed in response to pyridostigmine in the current study, may potentially be associated with clinically important reductions in mortality risk.

In conclusion, augmentation of parasympathetic tone with 30 mg of pyridostigmine in patients with stable CHF was well tolerated and significantly increased the heart rate recovery in the first minute after maximal exercise when compared with placebo. Since heart rate recovery is an independent predictor of mortality in patients with cardiovascular disease, further studies to assess long term safety and efficacy of pyridostigmine in heart failure are warranted.

ACKNOWLEDGEMENTS

We gratefully acknowledge the assistance received from Dr Ary L. Goldberger and staff of the NIH/NCRR Research Resource for Complex Physiologic Signals at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA in analysis of the heart rate recovery data and review of the manuscript. Supported in part by Division of Research Resources, Core Lab Facility in the General Clinical Research Center at Yale University, NIH, 5 MO1 RR00125, American Heart Association (Heritage Affiliate) Post-doctoral Fellowship Award (SA), and NHLBI grant HL K24–04024 (SDK).

REFERENCES

Thinned myocardial fibrosis with thrombus in the dilated form of hypertrophic cardiomyopathy demonstrated by multislice computed tomography

A 65 year old man with hypertrophic cardiomyopathy presented at our hospital because of dyspnoea on effort. An echocardiogram revealed a very large hypertrophy of the interventricular septum (IVS) with reduced apical wall motion and thinning of the apical wall of the left ventricle (LV), but a thrombus could not be observed in the LV. Therefore, we suspected the dilated form of hypertrophic cardiomyopathy. To evaluate the characteristics of the myocardium and to determine if a thrombus existed in the LV, ECG gated enhanced multislice computed tomography (CT) (Light Speed Ultra, General Electric, Milwaukee, Wisconsin, USA) was performed with a 1.25 mm slice thickness, helical pitch 3.25. Following intravenous injection of 100 ml of iodinated contrast material (350 mgI/ml), CT scanning was performed with retrospective ECG gated reconstruction at 30 seconds and eight minutes after the injection, and volume data were extracted from end diastole. In the axial source images and multiplanar reconstruction images representing the long axis of the LV, a thrombus and thinning of the wall in the apex of the LV (arrowheads) could be observed with a huge hypertrophy of IVS in the early phase. In the late phase, the thinned wall of the apical portion of the LV and the apical wall of the right ventricle (RV) were abnormally enhanced, compared with the huge, hypertrophic IVS, suggesting that they had caused fibrotic change. Since the reduced apical motion of the LV identified by the echocardiogram, caused by fibrotic change identified by CT, might produce large thrombi, anticoagulant treatment was initiated.

N Funabashi
K Yoshida
I Komuro
komuro-tky@umin.ac.jp

www.heartjnl.com
Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure
A S Androne, K Hryniewicz, R Goldsmith, A Arwady and S D Katz

*Heart* 2003 89: 854-858
doi: 10.1136/heart.89.8.854

Updated information and services can be found at:
http://heart.bmj.com/content/89/8/854

These include:

**References**
This article cites 30 articles, 9 of which you can access for free at:
http://heart.bmj.com/content/89/8/854#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

Drugs: cardiovascular system (8842)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/